FHA
AVTX icon

First Horizon Advisors’s Avalo Therapeutics AVTX Stock Holding History

First Horizon Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$9 – 2292
2023
Q4 		$9 Hold
1
– – ﹤0.01% 2358
2023
Q3 		$33 Hold
1
– – ﹤0.01% 2376
2023
Q2 		$98 Hold
1
– – ﹤0.01% 2430
2023
Q1 		$483 Buy
+1
New +$788 ﹤0.01% 2395

Other funds holding AVTX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $2.66B AUM 26.89% 1-Year Est. Return

First Horizon Advisors's AVTX Position: Q1 2024 in Review

First Horizon Advisors sold out of Avalo Therapeutics (AVTX) in Q1 2024, closing a stake of 1 share — an estimated $9 sold.

First Horizon Advisors first reported a position in AVTX in Q1 2023 and held it in 4 quarters. The position peaked at $483 in Q1 2023. 18 funds tracked by Wall St. Rank hold AVTX as of Q1 2024.

  • First Horizon Advisors reported no remaining Avalo Therapeutics position as of Q1 2024 after selling out during the quarter.
  • First Horizon Advisors sold 1 Avalo Therapeutics share in Q1 2024, an estimated $9.
  • First Horizon Advisors first reported a position in Avalo Therapeutics in Q1 2023 and held it in 4 quarters.
  • First Horizon Advisors's Avalo Therapeutics position peaked at $483 in Q1 2023.
  • 18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2024.

Based on First Horizon Advisors's 13F filing for Q1 2024, filed 26 Apr 2024.